Investment Rating - The report maintains a "Buy" rating for the company [6][8]. Core Insights - The company is a leading player in the orthopedic surgical robot industry in China, focusing on reshaping surgical processes through intelligent technology and integrating upstream and downstream resources [3][16]. - The company has launched multiple generations of orthopedic surgical robots, with significant advancements in product capabilities and regulatory approvals, including the first all-in-one orthopedic surgical robot [3][5]. - Recent policy changes from the National Medical Insurance Administration are expected to enhance the commercial viability of robotic surgeries, potentially increasing the number of procedures covered by insurance [4][48]. - The company’s revenue from consumables and services is projected to become a major growth driver, supported by an increasing number of surgeries and a growing aging population [5][28]. - Financial forecasts indicate strong revenue growth, with expected revenues of 275 million, 396 million, and 567 million yuan for 2025, 2026, and 2027 respectively, alongside a path to profitability by 2027 [6][9]. Company Overview - The latest closing price of the company's stock is 22.79 yuan, with a total market capitalization of 10.4 billion yuan [2]. - The company has a total share capital of 456 million shares, with a debt-to-asset ratio of 24.3% [2]. Business Model and Ecosystem - The company operates on a "device + consumables + services" model, which has led to synergistic growth across its business segments [24]. - The orthopedic surgical robot business is the core revenue source, with a significant number of surgeries performed using its products [25][29]. - The company has established a stable governance structure with a strong technical background among its management team, ensuring effective operational oversight [19][20]. Market Potential - The global orthopedic surgical robot market is projected to grow significantly, driven by an aging population and the increasing demand for precise surgical interventions [31][36]. - The domestic market for orthopedic surgical robots is expected to maintain high growth rates, with the company positioned as a market leader [41][42]. Financial Performance - The company has maintained a high gross margin, with a sales gross margin of 70.2% in 2024, which is expected to improve further [30]. - Revenue for the first three quarters of 2025 reached 1.87 billion yuan, reflecting a year-on-year growth of 103.5% [29][32].

证券研究报告·北交所公司深度报告·化学制品 锦华新材（920015） 精细化工基石稳固，电子化学品崭露头角 2026 年 02 月 03 日 买入（首次） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 1,115 | 1,239 | 1,064 | 1,209 | 1,507 | | 同比（%） | 12.13 | 11.21 | (14.18) | 13.67 | 24.63 | | 归母净利润（百万元） | 172.51 | 210.94 | 198.77 | 257.08 | 344.23 | | 同比（%） | 116.74 | 22.28 | (5.77) | 29.33 | 33.90 | | EPS-最新摊薄（元/股） | 1.27 | 1.56 | 1.47 | 1.90 | 2.54 | | P/E（现价&最新摊薄） | 39.17 | 32.04 | 34.00 | 26.29 | 19.63 | [Ta ...

[Table_Tag] [Table_Summary] 投资要点 证券研究报告·北交所公司深度报告·化学制品 锦华新材（920015） 精细化工基石稳固，电子化学品崭露头角 2026 年 02 月 03 日 买入（首次） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 1,115 | 1,239 | 1,064 | 1,209 | 1,507 | | 同比（%） | 12.13 | 11.21 | (14.18) | 13.67 | 24.63 | | 归母净利润（百万元） | 172.51 | 210.94 | 198.77 | 257.08 | 344.23 | | 同比（%） | 116.74 | 22.28 | (5.77) | 29.33 | 33.90 | | EPS-最新摊薄（元/股） | 1.27 | 1.56 | 1.47 | 1.90 | 2.54 | | P/E（现价&最新摊薄） | 39.17 | 32 ...

[Table_Page] 公司深度研究|汽车服务 [Table_Title] 中国汽研（601965.SH） 卡位稀缺，受益于中国汽车标准做大做强 [Table_Summary] 核心观点： 盈利预测： | [Table_ 单位 Finance] :人民币百万元 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入 | 4,007 | 4,697 | 4,967 | 5,866 | 7,171 | | 增长率（ % ） | 21.8% | 17.2% | 5.8% | 18.1% | 22.3% | | EBITDA | 1,306 | 1,678 | 1,956 | 2,278 | 2,673 | | 归母净利润 | 825 | 908 | 1,060 | 1,216 | 1,466 | | 增长率（ % ） | 19.7% | 10.0% | 16.8% | 14.7% | 20.6% | | EPS（元/股） | 0.82 | 0.90 | 1.06 | 1.21 | 1.46 | | ...

2026 年 02 月 03 日 中际旭创(300308.SZ) 红利 事件： 1 月 31 日，中际旭创发布全年业绩预告，公司预计 2025 年 1-12 月 业绩大幅上升，归属于上市公司股东的净利润为 98.00 亿至 118.00 亿，净利润同比增长 89.50%至 128.17%。公司预测业绩增长主要基 于：受益于算力需求，高速光模块等产品出货增加带动营收和利润提 升。虽然股份支付费用、存货与应收款减值损失、汇率下跌带来的汇 兑损失共计减少净利润约 6.06 亿元，但投资收益与公允价值变动损 益增加了净利润约 2.96 亿元，部分抵消了上述负面影响。 全球市场高速增长，需求远超供给: 全球 AI 算力建设正推动高端光模块需求高速增长，市场呈现"需求 远超供给"的紧平衡状态。根据 Lightcounting 预计，由于海内外科 技巨头（如 Alphabet、亚马逊、Meta、微软、阿里巴巴、腾讯、百度 等）创纪录的资本支出，当前包括光模块在内的许多产品需求超出供 应两倍以上。未来市场增速将直接取决于供应链的扩产能力。 增长的核心动力明确：一是 AI 基础设施对高速光模块与交换机的强 劲需求；二是光互连技 ...

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 53.84 CNY [4][7]. Core Insights - The company's short-term performance is under pressure due to intensified competition and policy impacts, leading to a downward revision of revenue and profit forecasts for 2025-2026 [4][10]. - Despite the short-term challenges, the company has significant long-term growth potential driven by self-research and innovation transformation [4][10]. - The company is expected to leverage its integrated service capabilities in contract research and development (CRO) and contract development and manufacturing organization (CDMO) to enhance its business structure and return to a growth trajectory [10]. - The company has a robust pipeline of self-researched products, with 132 projects under development, including 37 approved products, which are anticipated to contribute to stable revenue growth as they enter commercialization [10]. - The company is actively transitioning to innovative drug development, with 15 ongoing projects in key therapeutic areas, which could provide a second growth curve through partnerships and milestone payments [10]. Financial Summary - Revenue is projected to decline from 1,017 million CNY in 2023 to 696 million CNY in 2025, with a recovery to 889 million CNY by 2027 [6]. - The net profit attributable to the parent company is expected to turn negative in 2024 and 2025, with forecasts of -53 million CNY and -69 million CNY respectively, before recovering to 67 million CNY in 2027 [6]. - The earnings per share (EPS) is forecasted to be -0.63 CNY in 2025, with a recovery to 0.61 CNY by 2027 [6]. - The gross margin is expected to decrease from 65.5% in 2023 to 52.0% in 2024, before gradually improving to 56.4% by 2027 [6].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The issuance of H-share zero-coupon convertible bonds is expected to dilute H-share capital by 29.53% and total capital by 5.6%, with proceeds aimed at overseas business development and working capital supplementation. This is anticipated to have short-term pressure on the stock price, particularly in the Hong Kong market, but is expected to benefit long-term international business growth and enhance overall ROE [4][5][6] - The company maintains its profit forecast, projecting net profit attributable to shareholders of 168 billion, 217 billion, and 251 billion yuan for 2025-2027, representing year-on-year growth of 9%, 29%, and 16% respectively. The corresponding PE ratios are 12.2, 9.4, and 8.2 times, with a current PB of 1.20 times [4][6] Financial Summary - Revenue is projected to reach 37,078 million yuan in 2025, with a year-on-year decrease of 10.6%, followed by a recovery to 43,144 million yuan in 2026 and 48,837 million yuan in 2027, with growth rates of 16.4% and 13.2% respectively [7][10] - Net profit attributable to shareholders is expected to be 16,750 million yuan in 2025, 21,680 million yuan in 2026, and 25,067 million yuan in 2027, with year-on-year growth rates of 9.1%, 29.4%, and 15.6% respectively [7][10] - The company's gross margin is projected to improve from 51.2% in 2025 to 58.5% in 2027, while the net margin is expected to rise from 45.2% to 51.3% over the same period [7][10] Valuation Metrics - The projected PE ratios for the company are 12.2 for 2025, 9.4 for 2026, and 8.2 for 2027, indicating a favorable valuation trend [7][10] - The projected PB ratios are 1.2 for 2025, 1.1 for 2026, and 1.0 for 2027, suggesting a decreasing trend in the price-to-book ratio [7][10]

Investment Rating - The report assigns a "Buy" rating for the company, indicating a positive outlook following the divestiture of its real estate business and steady growth in the cosmetics segment [5][42]. Core Insights - The company has transitioned its main business focus to cosmetics and pharmaceuticals after divesting its real estate operations in 2023. The cosmetics segment has shown resilience, contributing over 52.8% of total revenue [10][41]. - The company is leveraging a "product + R&D + channel" strategy to build competitive advantages, focusing on marketing synergies, innovation in product development, and a comprehensive online and offline sales network [8][30][34]. - Revenue projections for 2025-2027 are estimated at RMB 38.1 billion, RMB 39.3 billion, and RMB 43.0 billion, with corresponding growth rates of -4.3%, +3.1%, and +9.5% respectively. Net profit is expected to reach RMB 2.4 billion, RMB 2.7 billion, and RMB 3.1 billion during the same period [9][41]. Summary by Sections Market Performance - The closing price of the stock is RMB 7.36, with a total market capitalization of RMB 7,481.95 million and a circulating market value of RMB 7,481.95 million [3]. Financial Data - The company reported a gross margin of 46.49% in 2023, a significant increase of 21.84 percentage points from the previous year, primarily due to the strategic shift away from low-margin real estate operations [21]. Revenue and Profit Forecast - The company anticipates a decline in revenue for 2023, followed by a gradual recovery, with net profit growth projected at +0.2%, +8.8%, and +15.3% for the years 2025 to 2027 [9][41]. Business Segments - The cosmetics segment is expected to see revenue growth of -5%, +6%, and +14% from 2025 to 2027, while the pharmaceutical segment is projected to grow at -5%, -3%, and +5% during the same period [10][41]. - The raw materials and additives segment is forecasted to grow steadily, with revenue increases of +3%, +4%, and +5% from 2025 to 2027 [10]. Competitive Positioning - The company is positioned favorably against comparable domestic brands, with a projected price-to-earnings (P/E) ratio of 28 times for 2026, aligning with industry averages [42]. Marketing and R&D Strategy - The company has invested significantly in R&D, with a budget of RMB 1.16 billion for the first three quarters of 2025, representing a research expense ratio of 4.47% [30]. - New product launches and marketing initiatives are focused on enhancing brand visibility and consumer engagement across various channels, including e-commerce and physical retail [28][34]. Sales Channels - The cosmetics segment's revenue is heavily driven by online sales, contributing 84.2% of total revenue, while offline sales account for 15.8% [34]. - The company is expanding its presence in both online and offline markets, establishing flagship stores on major e-commerce platforms and increasing the number of physical retail locations [34].

Investment Rating - The report maintains a "Buy" rating for the company [3][6] Core Insights - The company is expected to achieve a revenue of 6-7 billion yuan in 2025, representing a year-on-year growth of 410.87% to 496.02%, and a net profit of 1.85-2.15 billion yuan, marking a turnaround from losses [1] - The demand for AI computing power continues to rise, and the maturity of the cloud product line is driving large-scale commercialization across various sectors, including telecommunications, finance, and the internet [1][3] - The company's quarterly revenue is projected to increase, with Q4 2025 revenue estimated between 1.393 billion and 2.393 billion yuan, showing a sequential growth from Q3 2025 [1] Financial Projections - Revenue projections for 2025-2027 are 6.368 billion, 13.091 billion, and 20.953 billion yuan, respectively, with net profits expected to be 2.062 billion, 4.363 billion, and 7.018 billion yuan [3][5] - The company is expected to achieve an EPS of 4.89 yuan in 2025, increasing to 10.35 yuan in 2026 and 16.64 yuan in 2027 [5][10] - The net asset return rate is projected to improve significantly, reaching 18.0% in 2025 and 30.7% in 2027 [5][10] Market Position and Competitive Advantage - The company is positioned in the semiconductor industry, with leading technology in computing chips and accelerated customer adoption, enhancing business resilience and performance [3][6] - The launch of the Cambricon NeuWare software platform supports rapid migration and optimization of AI models, establishing a comprehensive system from self-developed chip architecture to high-performance software [2]

证券研究报告·公司点评报告 2026 年 2 月 3 日 江海证券研究发展部 机械军工行业研究组 执业证书编号：S1410524040001 | 投资评级： | 买入（维持） | | --- | --- | | 当前价格: | 69.37元 | | 市场数据 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 总股本(百万股) | | | 120.76 | | | | | | A 股股本(百万股) | | | 120.76 | | | | | | B/H 股股本(百万股) | | | -/- | | | | | | A 股流通比例(%) | | | 31.25 | | | | | | 个月最高/最低(元) | | | 88.98/36.60 | | 12 | | | | 第一大股东 | | | 蒋修华 | | | | | | 第一大股东持股比例(%) | | | 39.75 | | | | | | 上证综指/沪深 300 | | 4015.75/4605.98 | | | | | | | 数据来源：聚源 | 2 | | 日数据 ...